Physician profile
Nathaniel Collins
NPI 1245679422
$640.05
in general payments reported to CMS, 2019-2025
13 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $256 · 2024: $208 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $152.57 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $140.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $68.94 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.93 | 2024 | Jardiance |
| Ardelyx, INC. | $47.88 | 2023-2025 | Ibsrela |
| Corcept Therapeutics | $30.96 | 2025 | Korlym |
| Daiichi Sankyo INC. | $29.92 | 2023 | Injectafer |
| Lilly USA, LLC | $29.55 | 2023 | Mounjaro, Trulicity |
| Corium, LLC | $27.27 | 2023 | Adlarity |
| Amgen INC. | $15.11 | 2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.60 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $13.29 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $10.90 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.